Form 4: Ideaya Biosciences Executive Acquires Stock Options
SEC Form 4 Filing
Jason Throne, Chief Legal Officer of Ideaya Biosciences, acquired stock options for 125,500 shares on March 1, 2024.
Summary
- Jason Throne, Chief Legal Officer of Ideaya Biosciences, filed a Form 4 indicating changes in beneficial ownership.
- On March 1, 2024, Throne acquired stock options for 125,500 shares of Ideaya Biosciences common stock at an exercise price of $46.22.
- The options vest over four years, with 25% vesting on the first anniversary of the Vesting Commencement Date (January 1, 2024) and the remainder vesting monthly thereafter.
- Following the transaction, Throne directly owns options for 125,500 shares.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with company performance.
Stakeholder Impact
- The acquisition of stock options by a key executive may signal confidence in the company's future performance to shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/01/2024 | Vesting Commencement Date |
| 03/01/2024 | Date of Transaction: Acquisition of stock options |
| 03/04/2024 | Date of Form 4 Filing |
| 02/28/2034 | Expiration Date of Stock Options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.